Supernus Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2009
Net Income	1.32	60.71	53.42	126.95	113.06	110.99	57.28	91.22	13.94	-10.93	Upgrade
Depreciation & Amortization	84.86	85.54	32.6	18.14	6.66	7.06	8.13	2.4	0.92	0.93	Upgrade
Share-Based Compensation	26.76	17.57	17.91	16.56	14.85	11.29	8.43	5.93	4.09	2.86	Upgrade
Other Operating Activities	-1.85	-47	23.2	-23.25	8.57	-0.36	40.79	-32.73	15.57	-17.36	Upgrade
Operating Cash Flow	111.09	116.83	127.13	138.4	143.13	128.99	114.64	66.81	34.52	-24.5	Upgrade
Operating Cash Flow Growth	-4.91%	-8.10%	-8.14%	-3.30%	10.96%	12.51%	71.59%	93.52%	-	-	Upgrade
Capital Expenditures	-0.55	-0.41	-2.05	-3.69	-1.39	-0.84	-2.03	-1.6	-2.1	-0.59	Upgrade
Acquisitions	0	0	-298.8	-313.54	0	0	0	0	0	0	Upgrade
Change in Investments	269.28	-216.25	218.94	282.53	-156.54	-411.83	-73.23	-15.54	-26.28	0.21	Upgrade
Other Investing Activities	-	-	-	-	-	-0.81	-11.15	-18.82	-10.91	-2.28	Upgrade
Investing Cash Flow	268.73	-216.66	-81.91	-34.7	-157.92	-413.48	-86.42	-35.96	-39.29	-2.66	Upgrade
Share Issuance / Repurchase	6.61	12.42	7.1	4.36	3.93	77.27	5.68	2.05	1.87	0.57	Upgrade
Debt Issued / Paid	-402.5	0	-137.52	-0.8	0	299.17	0	0	0	0	Upgrade
Other Financing Activities	-1.99	-22.9	-	-	-	-	-	-	-	30	Upgrade
Financing Cash Flow	-397.88	-10.48	-130.42	3.56	3.93	376.44	5.68	2.05	1.87	30.57	Upgrade
Net Cash Flow	-18.07	-110.31	-85.21	107.26	-10.87	91.94	33.91	32.9	-2.9	3.42	Upgrade
Free Cash Flow	110.53	116.41	125.08	134.71	141.74	128.14	112.61	65.21	32.42	-25.09	Upgrade
Free Cash Flow Growth	-5.05%	-6.93%	-7.15%	-4.96%	10.61%	13.79%	72.69%	101.14%	-	-	Upgrade
Free Cash Flow Margin	18.19%	17.45%	21.57%	25.89%	36.09%	31.34%	37.26%	30.33%	21.98%	-27.07%	Upgrade
Free Cash Flow Per Share	2.03	2.17	2.36	2.56	2.70	2.46	2.22	1.32	0.68	-0.59	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).